Dorzolamide, increased peripapillary choroidal perfusion may be linked

Dorzolamide may increase peripapillary choroidal perfusion in patients with nonexudative age-related macular degeneration, according to a small study.

Alon Harris, PhD, and colleagues at the Indiana University School of Medicine randomized 36 patients with dry AMD in a 2:1 ratio to receive either placebo or topical dorzolamide.

Compared to the patients receiving placebo, those treated with dorzolamide showed a significantly increased rapidity of choroidal filling in the superior and inferior peripapillary regions. No significant difference in choroidal filling times was found in the perifoveal areas.

The study is published in the June issue of British Journal of Ophthalmology.